Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
CNS Spectr ; 25(3): 372-379, 2020 06.
Artigo em Inglês | MEDLINE | ID: mdl-31120009

RESUMO

OBJECTIVE: The AtWoRC study is an interventional, open-label Canadian study that demonstrated significant improvements in cognitive function and workplace productivity in patients with major depressive disorder (MDD) treated with vortioxetine for a current major depressive episode. The objective of the present analysis was to assess the Canadian economic impact of improved workplace productivity based on the AtWoRC study results. METHODS: The economic impact of improved productivity in patients with MDD treated with vortioxetine was assessed over a 52-week period considering productivity loss due to absenteeism and presenteeism using the standard human capital approach and an employer's perspective. Absenteeism was measured with the Work Productivity and Activity Impairment questionnaire; and presenteeism with the Work Limitation Questionnaire. Productivity gains following treatment initiation with vortioxetine were estimated using the difference from baseline. RESULTS: In the AtWoRC study, patients at baseline reportedly missed, in the past 7 days, an average of 8.1 h due to absenteeism and 3.0 h due to presenteeism. Following 52 weeks of treatment with vortioxetine, patients reportedly missed an average of 4.9 h due to absenteeism and 2.0 h due to presenteeism. This improved workplace productivity translated into savings of C$110.64 for 1 week of work following 52 weeks of treatment. The cumulative 52-week economic impact showed potential savings of C$4,550 when factoring in the cost of therapy. CONCLUSION: This study suggested that workplace productivity gain due to an improvement in symptoms of MDD following treatment with vortioxetine will lead to substantial cost savings for the Canadian economy.


Assuntos
Antidepressivos/uso terapêutico , Transtorno Depressivo Maior/economia , Retorno ao Trabalho/economia , Vortioxetina/uso terapêutico , Desempenho Profissional/economia , Adulto , Canadá , Cognição , Transtorno Depressivo Maior/tratamento farmacológico , Transtorno Depressivo Maior/epidemiologia , Eficiência , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Retorno ao Trabalho/estatística & dados numéricos
2.
BMC Public Health ; 18(1): 1130, 2018 Sep 19.
Artigo em Inglês | MEDLINE | ID: mdl-30231932

RESUMO

BACKGROUND: As a consequence of unfavourable epidemiological trends and the development of disease management, the economic aspects of heart failure (HF) have become more and more important. The costs of treatment (direct costs) appear to be the most frequently addressed topic in the economic research on HF; however, less is known about productivity losses (indirect costs) and the public finance burden attributable to the disease. Therefore, the aim of this study was to estimate the indirect costs and public finance consequences of HF in Poland in the period 2012-2015. METHODS: The study uses a societal perspective and a prevalence-based top-down approach to estimate the following components of HF indirect costs: absenteeism of the sick and their caregivers, presenteeism of the sick, disability, and premature mortality. The human capital method has been chosen to identify the value of productivity losses attributable to HF and the public finance consequences of the disease. Deterministic sensitivity analysis was performed to assess the robustness of the results. RESULTS: The total indirect costs of HF in Poland were €871.9 million in 2012, and they increased to €945.3 million in 2015. In the period investigated, these costs accounted for 0.212-0.224% of GDP, an equivalent of 22.63€-24.59€ per capita. Mortality proved to be the main driver of productivity losses, with 59.3-63.4% of the total costs depending on year, followed by presenteeism (21.1-22.5%), disability (11.1-14.2%) and the sick's absenteeism (3.3-4.0%). The cost of caregivers' absenteeism was unimportant. The social insurance expenditure for benefits associated with HF accounted for €40.7 million in 2012 and €45.6 million in 2015 (0.56-0.59% expenditure for all diseases). The potential public revenue losses associated with HF were €262.7-€287.9 million. Sensitivity analysis showed that the costs varied by - 12.1% to + 28.8% depending on the model parameter values. CONCLUSION: HF is a substantial burden on the economy and public finance in Poland. By confronting the disease more effectively, the length and quality of life for those affected by HF could be improved, but society as a whole could also benefit from the increased economic output.


Assuntos
Efeitos Psicossociais da Doença , Insuficiência Cardíaca/economia , Absenteísmo , Cuidadores , Pessoas com Deficiência/estatística & dados numéricos , Eficiência , Financiamento Governamental/economia , Financiamento Governamental/estatística & dados numéricos , Humanos , Mortalidade Prematura , Polônia , Presenteísmo/estatística & dados numéricos , Previdência Social/economia , Previdência Social/estatística & dados numéricos
3.
BMC Cancer ; 17(1): 676, 2017 Oct 10.
Artigo em Inglês | MEDLINE | ID: mdl-29017454

RESUMO

BACKGROUND: Apart from the health and social burden of the disease, breast cancer (BC) has important economic implications for the sick, health system and whole economy. There has been a growing interest in the economic aspects of breast cancer and analyses of the disease costs seem to be the most explored topic. However, the results from these studies are hardly comparable. With this study we aim to contribute to the field by providing estimates of productivity losses and public finance burden attributable to BC in Poland. METHODS: We used retrospective prevalence-based top-down approach to estimate the productivity losses (indirect costs) of BC in Poland in the period 2010-2014. Human capital method (HCM) and societal perspective were used to estimate the costs of: absenteeism of the sick and caregivers, presenteeism of the sick and caregivers, disability, and premature mortality. We also used figures illustrating public finance burden attributable to the disease. Deterministic sensitivity analysis was performed to assess the stability of the estimates. A variety of data sources were used with the social insurance system and Polish National Cancer Registry being the most important ones. RESULTS: Productivity losses associated with BC in Poland were €583.7 million in 2010 and they increased to €699.7 million in 2014. Throughout the period these costs accounted for 0.162-0.171% of GDP, an equivalent of 62,531-65,816 per capita GDP. Losses attributable to disability and premature mortality proved to be the major cost drivers with 27.6%-30.6% and 22.0%-24.6% of the total costs respectively. The costs due to caregivers' presenteeism were negligible (0.1% of total costs). Public finance expenditure for social insurance benefits to BC sufferers ranged from €50.2 million (2010) to €56.6 million (2014), an equivalent of 0.72-0.79% of expenditures for all diseases. Potential losses in public finance revenues accounted for €173.9 million in 2010 and €211.0 million in 2014. Sensitivity analysis showed that the results were robust to changes in the model parameters. CONCLUSIONS: The productivity losses attributable to BC in Poland were a sizable burden for the society. They contributed both to decreased economy output and to public finance deficit.


Assuntos
Neoplasias da Mama/economia , Neoplasias da Mama/epidemiologia , Adulto , Idoso , Neoplasias da Mama/patologia , Cuidadores , Efeitos Psicossociais da Doença , Eficiência , Feminino , Custos de Cuidados de Saúde , Humanos , Pessoa de Meia-Idade , Polônia/epidemiologia
4.
MDM Policy Pract ; 7(2): 23814683221113846, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35936828

RESUMO

Background. Traditional approaches to capturing health-related productivity loss (e.g., the human capital method) focus only on the foregone wages of affected patients, overlooking the losses caregivers can incur. This study estimated the burden of productivity loss among breast cancer (BC) and non-small-cell lung cancer (NSCLC) patients and individuals caring for such patients using an augmented multiplier method. Design. A cross-sectional survey of BC and NSCLC patients and caregivers measured loss associated with time absent from work (absenteeism) and reduced effectiveness (presenteeism). Respondents reported pre- and postcancer diagnosis income, hours worked, and time to complete tasks. Exploratory multivariable analyses examined correlations between respondents' clinical/demographic characteristics-including industry of employment-and postdiagnosis productivity. Results. Of 204 patients (104 BC, 100 NSCLC) and 200 caregivers (100 BC, 100 NSCLC) who completed the survey, 319 participants (162 BC, 157 NSCLC) working ≥40 wk/y prediagnosis were included in the analysis. More than one-third of the NSCLC (33%) and BC (43%) patients left the workforce postdiagnosis, whereas only 15% of caregivers did. The traditional estimate for the burden of productivity loss was 66% lower on average than the augmented estimate (NSCLC patients: 60%, BC patients: 69%, NSCLC caregivers: 59%, and BC caregivers: 73%). Conclusions. Although patients typically experience greater absenteeism, productivity loss incurred by caregivers is also substantial. Failure to account for such impacts can result in substantial underestimation of productivity gains novel cancer treatments may confer by enabling patients and caregivers to remain in the workforce longer. Our results underscore the importance of holistic approaches to understanding this impact on both patients and their caregivers and accounting for such considerations when making decisions about treatment and treatment value. Highlights: Cancer can have a profound impact on productivity. This study demonstrates how the disease affects not only patients but also the informal or unpaid individuals who care for patients.An augmented approach to calculating health-related productivity loss suggests that productivity impacts are much larger than previously understood.A more comprehensive understanding of the economic burden of cancer for both patients and their caregivers suggests the need for more support in the workplace for these individuals and a holistic approach to accounting for these impacts in treatment decision making.

5.
Eur J Health Econ ; 22(4): 531-545, 2021 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-33625624

RESUMO

BACKGROUND: Productivity costs result from loss of paid and unpaid work and replacements due to morbidity and mortality. They are usually assessed in health economic evaluations with human capital method (HCM) or friction cost method (FCM). The methodology for estimating lost productivity is an area of considerable debate. OBJECTIVE: To compare traditional and adjusted HCM and FCM productivity cost estimates among young stroke patients. METHODS: The Northern Finland Birth Cohort 1966 was followed until the age of 50 to identify all 339 stroke patients whose productivity costs were estimated with traditional, occupation-specific and adjusted HCM and FCM models by using detailed, national register-based data on care, disability, mortality, education, taxation and labour market. RESULTS: Compared to traditional HCM, taking into account occupational class, national unemployment rate, disability-free life expectancy and decline in work ability, the productivity cost estimate decreased by a third, from €255,960 to €166,050. When traditional FCM was adjusted for occupational class and national unemployment rate, the estimate more than doubled from €3,040 to €7,020. HCM was more sensitive to adjustments for discount rate and wage growth rate than FCM. CONCLUSIONS: This study highlights the importance of adjustments of HCM and FCM. Routine register-based data can be used for accurate productivity cost estimates of health shocks.


Assuntos
Eficiência , Acidente Vascular Cerebral , Efeitos Psicossociais da Doença , Finlândia/epidemiologia , Fricção , Humanos , Acidente Vascular Cerebral/epidemiologia
6.
Artigo em Inglês | MEDLINE | ID: mdl-31546662

RESUMO

The economic aspects of alcohol misuse are attracting increasing attention from policy makers and researchers but the evidence on the economic burden of this substance is hardly comparable internationally. This study aims to overcome this problem by estimating production losses (indirect costs) associated with alcohol-attributable mortality in 28 European Union (EU) countries in the year 2016. This study applies the prevalence-based top-down approach, societal perspective and human capital method to sex- and age-specific data on alcohol-related mortality at working age. The alcohol-attributable mortality data was taken from estimates based on the Global Burden of Disease Study 2016. Uniform data on labor and economic measures from the Eurostat database was used. The total production losses associated with alcohol-related deaths in the EU in 2016 were €32.1 billion. The per capita costs (share of costs in gross domestic product (GDP)) were €62.88 (0.215%) for the whole EU and ranged from €17.29 (0.062%) in Malta to €192.93 (0.875%) in Lithuania. On average, 81% of the losses were associated with male deaths and mortality among those aged 50-54 years generated the highest burden. Because alcohol is a major avoidable factor for mortality, public health community actions aimed at limiting this substance misuse might not only decrease the health burden but also contribute to the economic welfare of European societies.


Assuntos
Alcoolismo/economia , Alcoolismo/mortalidade , União Europeia/economia , Adulto , Efeitos Psicossociais da Doença , Bases de Dados Factuais , Feminino , Produto Interno Bruto , Humanos , Masculino , Pessoa de Meia-Idade , Prevalência , Saúde Pública
7.
Expert Rev Pharmacoecon Outcomes Res ; 18(1): 93-105, 2018 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-28796563

RESUMO

BACKGROUND: Growing public and private expenditure on healthcare results i.a. from the spreading of chronic diseases. Diabetes belongs to the most frequent ones, beyond neoplasms and cardiological diseases, and hence generates a significant burden for the public finance in terms of the direct costs. However, the economy suffers also from the indirect cost of diabetes that manifests itself in the loss in Gross Domestic Product (GDP) and general government revenues. METHODS: This paper aims to measure this indirect cost, both in terms of GDP drop (social perspective) and public revenue drop (public finance perspective), in the case of Poland in 2012-2014. We use a modified human capital approach and unique dataset provided by the Social Security institution in Poland and the Polish Central Statistical Office. RESULTS: Diabetes is a substantial and growing burden for the Polish economy. In the years 2012, 2013 and 2014 the indirect cost (output loss) amounted to 1.85 bn USD, 1.94 bn USD and 2.00 bn USD respectively. CONCLUSIONS: Estimated indirect cost of diabetes can be a useful input for health technology analyses of drugs or economic impact assessments of public health programmes.


Assuntos
Efeitos Psicossociais da Doença , Diabetes Mellitus/economia , Saúde Pública/economia , Diabetes Mellitus/epidemiologia , Produto Interno Bruto , Custos de Cuidados de Saúde/estatística & dados numéricos , Gastos em Saúde/estatística & dados numéricos , Humanos , Polônia
8.
Environ Sci Pollut Res Int ; 23(12): 11716-28, 2016 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-26944425

RESUMO

Aggravated air pollution in Beijing, China has caused serious health concern. This paper comprehensively evaluates the health losses from illness and premature death caused by air pollution in monetary terms. We use the concentration of PM10 as an indicator of the pollution since it constitutes the primary pollutant in Beijing. By our estimation, air pollution in Beijing caused a health loss equivalent to Ò°583.02 million or 0.03 % of its GDP. Most of the losses took the form of depreciation in human capital that resulted from premature death. The losses from premature deaths were most salient for people of either old or young ages, with the former group suffering from the highest mortality rates and the latter group the highest per capital losses of human capitals from premature death. Policies that target on PM10 emission reduction, urban vegetation expansion, and protection of vulnerable groups are all proposed as possible solutions to air pollution risks in Beijing.


Assuntos
Poluentes Atmosféricos/efeitos adversos , Poluição do Ar/efeitos adversos , Mortalidade , Material Particulado/efeitos adversos , Saúde Pública/economia , Poluentes Atmosféricos/economia , Poluição do Ar/economia , Poluição do Ar/estatística & dados numéricos , Pequim , China , Custos e Análise de Custo , Humanos , Modelos Econômicos , Material Particulado/economia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA